Rubraca Ovarian Cancer Maintenance Approval Brings PARP Inhibitor Parity On Broad Indication

US FDA approval of Rubraca's all-comers maintenance therapy for platinum-sensitive ovarian cancer continues model that Zejula and Lynparza used for a...

      

Related Stories

• The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
• Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?
• Xarelto Liability Suit: Is Labeling Silent About Increased Bleeding Risk?

 

Original Article: Rubraca Ovarian Cancer Maintenance Approval Brings PARP Inhibitor Parity On Broad Indication

More From BioPortfolio on "Rubraca Ovarian Cancer Maintenance Approval Brings PARP Inhibitor Parity On Broad Indication"